Scarica l'app Stockscreener
24.50
2.39%
-0.60
Dopo l'orario di chiusura:
24.51
0.01
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$25.10
Aprire:
$23.76
Volume 24 ore:
2.01M
Relative Volume:
1.45
Capitalizzazione di mercato:
$4.99B
Reddito:
-
Utile/perdita netta:
$-464.20M
Rapporto P/E:
-9.134
EPS:
-2.6823
Flusso di cassa netto:
$-423.09M
1 W Prestazione:
-3.39%
1M Prestazione:
-11.71%
6M Prestazione:
+46.44%
1 anno Prestazione:
+49.21%
Intervallo 1D:
$23.24
$25.37
Intervallo di 1 settimana:
$23.24
$25.86
Portata 52W:
$12.72
$29.25
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
24.50 | 4.99B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Mkt Perform |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT - MarketBeat
Immunovant falls on late-stage trial setback for TED therapy - MSN
Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock - MarketBeat
Immunovant (IMVT) CEO Venker sells $342,854 in shares By Investing.com - Investing.com India
Immunovant (IMVT) CEO Venker sells $342,854 in shares - Investing.com
Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock - Stock Titan
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
IMVT Should I Buy - Intellectia AI
Truist reiterates Hold on Immunovant stock after trial failure By Investing.com - Investing.com India
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant's treatment for eye disease fails in late-stage trials - Reuters
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data UpdateSlideshow - seekingalpha.com
IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy - TradingView
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - finance.yahoo.com
Leerink cuts Immunovant stock price target on failed TED trial By Investing.com - au.investing.com
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - BioPharma Dive
Leerink cuts Immunovant stock price target on failed TED trial - Investing.com
Oppenheimer maintains Immunovant stock rating on next-gen drug focus - Investing.com UK
Oppenheimer maintains Immunovant stock rating on next-gen drug focus By Investing.com - au.investing.com
IMVT: Batoclimab missed its Phase 3 endpoint in thyroid eye disease; focus shifts to IMVT-1402 - TradingView
Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights
Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials By Investing.com - Investing.com Canada
Hennion & Walsh Asset Management Inc. Makes New Investment in Immunovant, Inc. $IMVT - MarketBeat
Immunovant’s batoclimab fails Phase 3 thyroid eye disease trials - Investing.com
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - Bitget
Two late-stage thyroid eye disease trials miss for Immunovant - Stock Titan
Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results - MSN
Sjögren’s Syndrome Market Poised for Significant Expansion Through 2034, Driven by Advancing Pipeline Therapies and Rising Disease Burden | DelveInsight Analysis Featuring Astellas Pharma, Immunovant - Barchart.com
Responsive Playbooks and the IMVT Inflection - Stock Traders Daily
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - AOL.com
EPS Watch: Does PCOR have consistent dividend growthExit Point & Fast Moving Stock Watchlists - baoquankhu1.vn
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com India
Top Immunovant Executive Quietly Cashes Out in Notable Insider Stock Move - TipRanks
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - MarketBeat
Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com - Investing.com South Africa
Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan
Bernstein initiates Immunovant stock coverage with neutral rating - Investing.com UK
Bernstein initiates Immunovant stock coverage with neutral rating By Investing.com - Investing.com Australia
Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein - MarketBeat
Understanding the Setup: (IMVT) and Scalable Risk - Stock Traders Daily
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position - MarketBeat
Immunovant, Inc. $IMVT Shares Purchased by Granahan Investment Management LLC - MarketBeat
HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT - MarketBeat
Truist Securities Initiates Coverage of Immunovant (IMVT) with Hold Recommendation - MSN
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):